nach oben

Erschienen in:

01.09.2012 | Original Paper

Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy

verfasst von: Buntaro Fujita, Marcus Franz, Bjoern Goebel, Michael Fritzenwanger, Hans R. Figulla, Friedhelm Kuethe, Markus Ferrari, Christian Jung

Erschienen in: Clinical Research in Cardiology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Reduction of resting heart rate (HR) has been suggested as a novel therapeutic approach in patients with chronic heart failure because it has been shown to prolong survival and also to improve health-related quality of life (Hr-QoL). The purpose of this analysis was to assess the prognostic impact of resting HR in patients with dilated cardiomyopathy (DCM).

Methods

217 patients with DCM confirmed by endomyocardial biopsy were investigated (age 49 ± 11 years, 20.7 % were female). The study population was divided into two groups according to the median of the resting HR. After a median follow-up time of 7.4 years overall survival and health-related quality of life (Hr-QoL) were compared in both groups. Survival was compared using Kaplan–Meier method and Hr-QoL was assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ).

Results

Elevated resting HR was associated with poor 1-year survival (p = 0.03). In contrast, long-term survival was not affected by HR (p = 0.20). Patients with lower HR at rest scored significantly lower on the MLHFQ (20 vs. 36, p = 0.03), indicating that higher resting HR is associated with an impairment of Hr-QoL.

Conclusions

Increased HR might be used as a diagnostic tool to identify patients at risk. Reduction of resting HR in patients with DCM might be a therapeutic option to improve Hr-QoL and therefore merits further investigation in future studies.

Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2010) Executive summary: heart disease and stroke statistics—2010 update. Circulation 121(7):948–954. doi:10.1161/circulationaha.109.192666 PubMedCrossRef

Krum H, Teerlink JR (2011) Medical therapy for chronic heart failure. The Lancet 378(9792):713–721. doi:10.1016/S0140-6736(11)61038-6 CrossRef

Ferrari R, Ceconi C (2011) Selective and specific if inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 9(8):959–973. doi:10.1586/erc.11.99 PubMedCrossRef

Reil J-C, Custodis F, Swedberg K, Komajda M, Borer J, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100(1):11–19. doi:10.1007/s00392-010-0207-x PubMedCrossRef

Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807–816. doi:10.1016/S0140-6736(08)61170-8 PubMedCrossRef

Tardif J-C, Ponikowski P, Kahan T (2009) Efficacy of the if current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540–548. doi:10.1093/eurheartj/ehn571 PubMedCrossRef

Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U (2012) Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol, pp 1–9. doi:10.1007/s00392-011-0402-4

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337–2345. doi:10.1093/eurheartj/ehp358 PubMedCrossRef

Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100(2):121–128. doi:10.1007/s00392-010-0220-0 PubMedCrossRef

10.

Kolloch R, Legler UF, Champion A, Cooper-DeHoff RM, Handberg E, Zhou Q, Pepine CJ (2008) Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29(10):1327–1334. doi:10.1093/eurheartj/ehn123 PubMedCrossRef

11.

Rambihar S, Gao P, Teo K, Bohm M, Yusuf S, Lonn E, On Behalf of the ONTARGET/TRANSCEND Investigators (2010) Abstract 12667: heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease—an analysis of ONTARGET/TRANSCEND. Circulation 122(21 Supplement):A12667

12.

Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19):2395–2404. doi:10.1093/eurheartj/ehr343 PubMedCrossRef

13.

Mommersteeg PMC, Denollet J, Spertus JA, Pedersen SS (2009) Health status as a risk factor in cardiovascular disease: a systematic review of current evidence. Am Heart J 157(2):208–218. doi:10.1016/j.ahj.2008.09.020 PubMedCrossRef

14.

Morgan K, McGee H, Shelley E (2007) Quality of life assessment in heart failure interventions: a 10-year (1996–2005) review. J Cardiovasc Risk 14(5):589–607. doi:10.1097/HJR.0b013e32828622c3

15.

O’Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson J (1986) Dilated cardiomyopathy: emerging role of endomyocardial biopsy. Curr Probl Cardiol 11(8):448–507. doi:10.1016/0146-2806(86)90029-0 CrossRef

16.

Olsen EG (1979) The pathology of cardiomyopathies. A critical analysis. Am Heart J 98(3):385–392. doi:10.1016/0002-8703(79)90052-8 PubMedCrossRef

17.

Luk A, Ahn E, Soor GS, Butany J (2009) Dilated cardiomyopathy: a review. J Clin Pathol 62(3):219–225. doi:10.1136/jcp.2008.060731 PubMedCrossRef

18.

Yonesaka S, Becker AE (1987) Dilated cardiomyopathy: diagnostic accuracy of endomyocardial biopsy. Br Heart J 58(2):156–161. doi:10.1136/hrt.58.2.156 PubMedCrossRef

19.

Garin O, Ferrer M, Pont À, Rué M, Kotzeva A, Wiklund I, Van Ganse E, Alonso J (2009) Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res 18(1):71–85. doi:10.1007/s11136-008-9416-4 PubMedCrossRef

20.

Bennett SJ, Oldridge NB, Eckert GJ, Embree JL, Browning S, Hou N, Deer M, Murray MD (2002) Discriminant properties of commonly used quality of life measures in heart failure. Qual Life Res 11(4):349–359. doi:10.1023/A:1015547713061 CrossRef

21.

Quittan M, Wiesinger GF, Crevenna R, Nuhr MJ, Posch M, Hülsmann M, Müller D, Pacher R, Fialka-Moser V (2001) Cross-cultural adaptation of the Minnesota Living with Heart Failure Questionnaire for German-speaking patients. J Rehabil Med 33(4):182–186. doi:10.1080/16501970121386 PubMedCrossRef

22.

Ceconi C, Guardigli G, Rizzo P, Francolini G, Ferrari R (2011) The heart rate story. Eur Heart J Suppl 13(suppl C):C4–C13. doi:10.1093/eurheartj/sur014 CrossRef

23.

Morrissey RP, Czer L, Shah PK (2011) Chronic heart failure: current evidence, challenges to therapy, and future directions. Am J Cardiovasc Drugs 11(3):153–171. doi:10.2165/11592090-000000000-00000 PubMedCrossRef

24.

Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117(18):2377–2387. doi:10.1161/circulationaha.107.746537 PubMedCrossRef

25.

Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE (2008) Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 126(3):302–312. doi:10.1016/j.ijcard.2007.08.077 PubMedCrossRef

26.

Lang CC, Gupta S, Kalra P, Keavney B, Menown I, Morley C, Padmanabhan S (2010) Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: clinical evidence and pathophysiological mechanisms. Atherosclerosis 212(1):1–8. doi:10.1016/j.atherosclerosis.2010.01.029 PubMedCrossRef

27.

Hasenfuss G, Holumbarsch C, Hermann H-P, Astheimer K, Pleske B, Just H (1994) Influence of the force—frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 15(2):164–170PubMed

28.

Clements IP, Miller WL, Olson LJ (1999) Resting heart rate and cardiac function in dilated cardiomyopathy. Int J Cardiol 72(1):27–37. doi:10.1016/S0167-5273(99)00139-4 PubMedCrossRef

29.

Rayan M, Tawfik M, Alabd A, Gamal A (2011) Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy? Anadolu Kardiyol Derg 11(5):402–406. doi:10.5152/akd.2011.110 PubMed

30.

Gillman MW, Kannel WB, Belanger A, Dagostino RB (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125(4):1148–1154. doi:10.1016/0002-8703(93)90128-V PubMedCrossRef

31.

Thomas F, Rudnichi A, Bacri A-M, Bean K, Guize L, Benetos A (2001) Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 37(5):1256–1261. doi:10.1161/01.HYP.37.5.1256 PubMedCrossRef

32.

Shah MR, Hasselblad V, Stinnett SS, Kramer JM, Grossman S, Gheorghiade M, Adams KF, Swedberg K, Califf RM, O’Connor CM (2002) Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 4(3):297–304. doi:10.1016/S1388-9842(01)00202-1 PubMedCrossRef

33.

Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T (2011) Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 13(9):1013–1018. doi:10.1093/eurjhf/hfr072 PubMedCrossRef

34.

Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT (1994) Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 23(2):393–400. doi:10.1016/0735-1097(94)90426-X PubMedCrossRef

35.

Evangelista LS, Moser DK, Westlake C, Hamilton MA, Fonarow GC, Dracup K (2006) Impact of obesity on quality of life and depression in patients with heart failure. Eur J Heart Fail 8(7):750–755. doi:10.1016/j.ejheart.2006.02.004 PubMedCrossRef

36.

Fujita B, Lauten A, Goebel B, Franz M, Fritzenwanger M, Ferrari M, Figulla H, Kuethe F, Jung C (2011) Impact of diabetes mellitus on quality of life in patients with congestive heart failure. Qual Life Res. doi:10.1007/s11136-011-0039-9 PubMed

37.

Hallas CN, Wray J, Andreou P, Banner NR (2011) Depression and perceptions about heart failure predict quality of life in patients with advanced heart failure. Heart Lung J Acute Crit Care 40(2):111–121. doi:10.1016/j.hrtlng.2009.12.008 CrossRef

Titel: Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy
verfasst von: Buntaro Fujita
Marcus Franz
Bjoern Goebel
Michael Fritzenwanger
Hans R. Figulla
Friedhelm Kuethe
Markus Ferrari
Christian Jung
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Clinical Research in Cardiology / Ausgabe 9/2012
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-012-0447-z

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Interventional closure of atrial septal defects without fluoroscopy in adult and pediatric patients

Cardiogoniometry as a diagnostic tool in patients with acute coronary syndromes: results of the CGM@ACS trial

Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension

Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry

Retrograde, transsubclavian implantation of a SAPIEN XT™ aortic valve prosthesis with the Edwards NovaFlex+™ system

Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie